Dasatinib in Treating Patients With Metastatic Pancreatic Cancer

Status Completed

Clinical Trial Summary

Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase II trial is studying how well dasatinib works in treating patients with metastatic pancreatic cancer.

Clinical Trial Description

PRIMARY OBJECTIVE:

I. Determine the overall survival, including median survival, of patients with metastatic adenocarcinoma of the pancreas treated with dasatinib.

SECONDARY OBJECTIVES:

I. Determine the effects of this drug on quantities of circulating tumor cells in these patients.

II. Determine the time to progression in patients treated with this drug. III. Determine pre- and post-drug fat-free mass and gait speed in patients treated with this drug.

IV. Evaluate the toxicity of this drug in these patients. V. Evaluate objective response rate in patients treated with this drug.

OUTLINE: This is an open-label, multicenter study.

Patients receive oral dasatinib twice daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.

Patients undergo blood collection at baseline and during days 25-31. Samples are analyzed for quantification of circulating tumor cells. Patients also undergo analysis of fat-free mass and gait speed at baseline and at 1, 2, and 6 months.

After completion of study treatment, patients are followed periodically. ;

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00474812
Study type	Interventional
Source	National Cancer Institute (NCI)
Contact
Status	Completed
Phase	Phase 2
Start date	May 2007
Completion date	February 2014

View Details

See also
Status	Clinical Trial	Phase
Terminated	`NCT02495896` - Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors	Phase 1
Completed	`NCT02005315` - A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer	Phase 1
Completed	`NCT01453153` - Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer	Phase 1/Phase 2
Completed	`NCT01064622` - Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer	Phase 1/Phase 2
Completed	`NCT00095966` - Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	Phase 2
Completed	`NCT02178436` - Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer	Phase 1/Phase 2
Completed	`NCT01846520` - Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers	N/A
Completed	`NCT01647828` - A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer	Phase 1/Phase 2
Terminated	`NCT01555489` - Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca	Phase 2
Completed	`NCT01191684` - Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer	Phase 1
Completed	`NCT01232829` - Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer	Phase 2
Terminated	`NCT01233505` - Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT00735917` - Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer	Phase 2
Completed	`NCT02896907` - Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery	Early Phase 1
Completed	`NCT02307539` - Palliative Care in Improving Quality of Life in Patients With Newly Diagnosed Pancreatic Cancer	N/A
Completed	`NCT02050178` - Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer	Phase 1
Completed	`NCT01488552` - Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer	Phase 1/Phase 2
Completed	`NCT01222689` - Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	Phase 2
Completed	`NCT00397787` - Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine	Phase 2
Completed	`NCT00028496` - Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer	Phase 1